BRD4 bimodal binding at promoters and drug-induced displacement at Pol II pause sites associates with I-BET sensitivity

por Khoueiry, P., Ward Gahlawat, A., Petretich, M., Michon, A. M., Simola, D., Lam, E., Furlong, E. E., Benes, V., Dawson, M. A., Prinjha, R. K., Drewes, G., Grandi, P.
Publicado 2019

Systematic chemical and molecular profiling of MLL-rearranged infant acute lymphoblastic leukemia reveals efficacy of romidepsin

por Cruickshank, M N, Ford, J, Cheung, L C, Heng, J, Singh, S, Wells, J, Failes, T W, Arndt, G M, Smithers, N, Prinjha, R K, Anderson, D, Carter, K W, Gout, A M, Lassmann, T, O'Reilly, J, Cole, C H, Kotecha, R S, Kees, U R
Publicado 2017

Recurrent mutations, including NPM1c, activate a BRD4-dependent core transcriptional program in acute myeloid leukemia

por Dawson, M A, Gudgin, E J, Horton, S J, Giotopoulos, G, Meduri, E, Robson, S, Cannizzaro, E, Osaki, H, Wiese, M, Putwain, S, Fong, C Y, Grove, C, Craig, J, Dittmann, A, Lugo, D, Jeffrey, P, Drewes, G, Lee, K, Bullinger, L, Prinjha, R K, Kouzarides, T, Vassiliou, G S, Huntly, B J P
Publicado 2014